Re-challenge with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‑TKI)
has been suggested to potentially improve survival in certain populations of patients with …

Carcinomatous meningitis (CM) is a severe complication of lung cancer. Here, we report on
two EGFR-mutated patients who attained relatively long survivals by erlotinib treatment after …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
became an attractive therapeutic option for advanced non-small-cell lung cancer (NSCLC) …

We report a Chinese male patient with advanced stage lung squamous cell carcinoma who
developed brain metastases after responding to treatment comprising six cycles of …

After the failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-
TKI) therapy, some non-small cell lung cancer patients desire to receive switching with …

Background: To investigate the relationships among the clinical characteristics, different
EGFR-TKIs, and osimertinib treatment in different treatment lines. Methods: We …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are established
treatment for non-small cell lung cancer (NSCLC). However, after initial response to the …

We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection,
which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any …

The epidermal growth factor receptor (EGFR) is an attractive anti-cancer target in non-small
cell lung cancer. The small-molecule agents such as erlotinib and gefitinib that selectively …